Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
IPO Year: 2015
Exchange: NASDAQ
Website: glpg.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/14/2025 | $31.00 → $22.00 | Equal-Weight → Underweight | Morgan Stanley |
| 11/20/2024 | Hold → Reduce | Kepler | |
| 9/9/2024 | $24.00 | Market Perform | Leerink Partners |
| 8/2/2024 | Outperform → Mkt Perform | Raymond James | |
| 3/28/2024 | $41.00 → $31.00 | Neutral → Underperform | BofA Securities |
| 3/7/2024 | $38.00 | Equal-Weight | Morgan Stanley |
| 8/24/2023 | Buy → Neutral | Citigroup | |
| 5/5/2023 | Mkt Perform → Outperform | Raymond James | |
| 1/23/2023 | $49.00 → $47.20 | Underperform → Hold | Jefferies |
| 11/7/2022 | Outperform → Mkt Perform | Raymond James |
Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that new data from our ongoing ATALANTA-1 Phase 1/2 study of GLPG5101 in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) have been accepted for oral presentations at the 2025 European Hematology Association (EHA) Congress taking place June 12-15, 2025, in Milan, Italy, and the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland the following week. "At Galapagos, we are driven by a mission to expand access to transformative cell therapies for pa
Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives for its existing businesses, including cell therapy, with a focus on maximizing resources available for transformative business development transactions Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as CEO of Galapagos, effective immediately, succeeding Dr. Paul Stoffels who announced his retirement in April 2025 Mr. Jérôme Contamine, formerly Lead Non-Executive Director, has been appointed Chair of the Board of Directors of Galapagos, replacing Dr. Paul Stoffels Mechelen, Belgium; May 13, 2025,
First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -
Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as founding CEO of newly created SpinCo Dr. Paul Stoffels, Chair and CEO of Galapagos, plans to retire as CEO upon appointment of successor in the next 12 months and plans to continue as Chair of the Board of Directors, ensuring leadership continuity and long-term strategic guidance Mechelen, Belgium; April 21, 2025, 22:10 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today makes two executive leadership announcements. In line with its planned separation
Mechelen, Belgium; April 15, 2025, 07:30 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced the departure of its CFO and COO, Thad Huston, effective as of August 1, 2025. Mr. Huston has decided to leave the company and return to the U.S. for personal and professional reasons. Mr. Huston joined Galapagos NV in 2023 from Kite Pharma, Inc., to support Galapagos' transformation into a cell therapy company. The company expects to announce Mr. Huston's successor in the coming months.Paul Stoffels1, MD, CEO and Chair of the B
Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders' Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 CET at the registered office of the Company. The annual report for the financial year 2024, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF. The annual 2024 Form 20-F filing with the SEC is available at www.sec.gov/edgar. Galapagos has the honor to invite its shareholders, holders of subscription rights, Board members, and
Mechelen, Belgium; February 24, 2025, 22:01 CET – Galapagos NV ((Euronext &, NASDAQ:GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that its management will present at the following investor conferences in March:TD Cowen 45th Annual Healthcare Conference Date: Tuesday, March 4, 2025Location: Boston, MACorporate Presentation: 1:50 - 2:20 PM ET / 7:50 - 8:20 PM CETLive Webcast Link: HereBarclays 27th Annual Global Healthcare ConferenceDate: Wednesday, March 12, 2025Location: Miami, FLCorporate Presentation: 11:00 - 11:25 AM ET / 5:00 - 5:25 PM CETLive Webcast Link: HereA live webcast of the presentat
Mechelen, Belgium; February 17, 2025, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) received a transparency notification and 13D filing from Tang Capital. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on February 14, 2025 on behalf of Mr. Kevin Tang, Tang Capital Management, LLC ("TCM"), Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI"), and Tang Capital Partners III, Inc. ("TCP III"), who notified us that TCP and TCPI hold an aggregate of 887,227 ordinary shares and that TCP, TCPI, and TCP III hold an aggregate of 2,436,180 American Depository Receipts ("ADRs") (each of which rep
Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein Focusing on accelerating GLPG5101 program, expanding to eight indications with significant unmet needs, and aiming for first approval by 2028 Plan to separate into two companies listed on Nasdaq and Euronext, with SpinCo to build a pipeline through deals and Galapagos to advance novel cell therapies for cancers of high unmet need Management to host conference call tomorrow, February 13, 2025, at 14:00 CET / 8:00 am ET Mechelen, Belgium; February 12, 2025, 22:01 CET; regulated information – G
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network Galapagos to implement a strategic reorganization to position the Company for long-term growth and cell therapy leadership in oncologyManagement to host conference call today at 14:00 CET / 8:00 am ET MECHELEN, Belgium – January 8, 2025 – 07:30 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GL
Morgan Stanley downgraded Galapagos NV from Equal-Weight to Underweight and set a new price target of $22.00 from $31.00 previously
Kepler downgraded Galapagos NV from Hold to Reduce
Leerink Partners initiated coverage of Galapagos NV with a rating of Market Perform and set a new price target of $24.00
Raymond James downgraded Galapagos NV from Outperform to Mkt Perform
BofA Securities downgraded Galapagos NV from Neutral to Underperform and set a new price target of $31.00 from $41.00 previously
Morgan Stanley resumed coverage of Galapagos NV with a rating of Equal-Weight and set a new price target of $38.00
Citigroup downgraded Galapagos NV from Buy to Neutral
Raymond James upgraded Galapagos NV from Mkt Perform to Outperform
Jefferies upgraded Galapagos NV from Underperform to Hold and set a new price target of $47.20 from $49.00 previously
Raymond James downgraded Galapagos NV from Outperform to Mkt Perform
Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives for its existing businesses, including cell therapy, with a focus on maximizing resources available for transformative business development transactions Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as CEO of Galapagos, effective immediately, succeeding Dr. Paul Stoffels who announced his retirement in April 2025 Mr. Jérôme Contamine, formerly Lead Non-Executive Director, has been appointed Chair of the Board of Directors of Galapagos, replacing Dr. Paul Stoffels Mechelen, Belgium; May 13, 2025,
Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders' Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 CET at the registered office of the Company. The annual report for the financial year 2024, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF. The annual 2024 Form 20-F filing with the SEC is available at www.sec.gov/edgar. Galapagos has the honor to invite its shareholders, holders of subscription rights, Board members, and
Mechelen, Belgium; October 7, 2024, 07:00 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today announced the appointment by way of co-optation of Oleg Nodelman as Non-Executive Non-Independent Director to its Board of Directors, effective October 7, 2024. Mr. Nodelman replaces Mr. Dan G. Baker who stepped down on October 6, 2024. The addition of Mr. Nodelman marks an important step in Galapagos' ongoing efforts to engage with shareholders and continue to execute on our Forward, Faster strategy to accelerate innovation and create near-and long-term value. "We are pleased to welcome Oleg Nodelman to the Galapagos Board," said Dr. Paul Stoffels, Galapagos' CEO and Chair of the Board of Direc
Publication of annual report for financial year 2023Annual Shareholders' Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board membersExtraordinary Shareholders' Meeting resolutions include approval of renewal of authorized capital and issuance of Gilead Subsequent Warrant B Mechelen, Belgium; 28 March 2024, 21.01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today publishes its annual report for the financial year 2023 and announces its Annual and Extraordinary Shareholders' Meetings (AGM and EGM) to be held sequentially on Tuesday, 30 April 2024 at 2:00 pm (CET) and 3:00 pm (CET), respectively, at the registered office of t
Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as Non-Executive Non-Independent Director by way of cooptation. Andrew Dickinson is Gilead's Chief Financial Officer (CFO) and replaces Daniel O'Day, Gilead's Chairman and Chief Executive Officer (CEO), who was a member of the Galapagos Board of Directors from 22 October 2019 to 26 March 2024. Mr. Dickinson joined Gilead in 2016. Prior to his current role as CFO, he served as head of the company's corporate development and strategy group. Before joining Gilead, Mr. Dickinson worked at Lazard as global c
Se NodThera Ltd ("NodThera" or the "Company") NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the appointment of Thomas Jaecklin, M.D., M.Sc., FMH as Chief Medical Officer (CMO), with effect from today. With more than 20 years of experience across global large pharma, biotech and academic medicine, Dr. Jaecklin is an accomplished late-stage drug development leader. He brings deep expertise across multiple therapy areas, including neuroscience and inflammation, with a strong track reco
Transaction expected to close in the first quarter of 2024, subject to customary closing conditionsMichele Manto, Galapagos' Chief Commercial Officer, to join Alfasigma Mechelen, Belgium; 02 January 2024, 07:00 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) and Alfasigma S.p.A. today announced that they have signed an agreement to transfer Galapagos' Jyseleca® (filgotinib) business to Alfasigma, marking a significant milestone in Galapagos' transformation into an innovative biotechnology company with a best-in-class research and development pipeline aimed at addressing high unmet patient needs in immunology and oncology. The agreement follows the signing of a letter of intent as announced on
Mechelen, Belgium; 19 September 2023, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that during its meeting of 19 September 2023, the Board of Directors appointed Mr. Simon Sturge as Non-Executive Independent Director by way of cooptation. Mr. Sturge replaces Dr. Mary Kerr who stepped down on 18 September 2023. Mr. Sturge brings over 40 years of international biotech and pharma experience with leadership positions at Merck KGaA and Boehringer Ingelheim. He held CEO roles at several biotech companies, including Kymab (now Sanofi) and Celltech Biologics (now Lonza), and founded Ribotargets (now Vernalis). Mr. Sturge is currently Chairman of the Board of Directors of Moo
Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023. Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos from Kite, a Gilead Company (NASDAQ:GILD). He brings 30 years of global finance and operational experience in healthcare with an excellent track record of driving business transformation and innovation. "On behalf of the Board of Directors and management of Galapagos, I extend a warm welcome to Thad. Thad is a widely recognized leader with a strong internationa
Mechelen, Belgium; 12 June 2023, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that during its meeting of 12 June 2023, the Board of Directors co-opted Dr. Susanne Schaffert as non-executive independent Director. Dr. Schaffert replaces Dr. Rajesh Parekh who stepped down on 10 June 2023. After an extraordinary 27-year career at Novartis in various global roles, including commercialization, market access, investor relations, business development & licensing, acquisitions and company integration, Dr. Schaffert retired in 2022 as President of Novartis Oncology and Member of the Novartis Executive Committee. In that role, Dr. Schaffert ran a global $15 billion business acr
First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028 Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed Founding CEO of Galapagos subsidiary SpinCo €3.3 billion in cash and financial investments as of March 31, 2025; Normalized annual cash burn guidance, excluding restructuring costs, in the range of €175 million -
Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein Focusing on accelerating GLPG5101 program, expanding to eight indications with significant unmet needs, and aiming for first approval by 2028 Plan to separate into two companies listed on Nasdaq and Euronext, with SpinCo to build a pipeline through deals and Galapagos to advance novel cell therapies for cancers of high unmet need Management to host conference call tomorrow, February 13, 2025, at 14:00 CET / 8:00 am ET Mechelen, Belgium; February 12, 2025, 22:01 CET; regulated information – G
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network Galapagos to implement a strategic reorganization to position the Company for long-term growth and cell therapy leadership in oncologyManagement to host conference call today at 14:00 CET / 8:00 am ET MECHELEN, Belgium – January 8, 2025 – 07:30 CET; regulated information – inside information – Galapagos NV ((Euronext &, NASDAQ:GL
We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy.We are committed to addressing the high unmet needs of patients through a growing cell therapy and small molecule pipeline with breakthrough potential. This includes more than 20 programs, with four assets in clinical development across 11 indications, and more than 15 preclinical programs in oncology and immunology. We achieved a major regulatory milestone with the FDA clearance of the Investigational New Drug (IND) application for the Phase 1/2 ATALANTA-1 study of our CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL), marking an important s
Executing on our Forward, Faster strategy with strong progress in a pivotal year, focused on delivering regulatory and clinical milestones, expanding our cell therapy manufacturing capabilities, and advancing our early-stage programs.Submitted IND application to FDA for our Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101 in R/R NHL.Submitted CTA to EMA for our Phase 2 study of GLPG5201 in R/R CLL with or without RT.IND filing for our Phase 1/2 EUPLAGIA-1 study of CD19 CAR-T candidate GLPG5201 in R/R CLL with or without RT on track for Q4 2024.Encouraging new Phase 1/2 safety, efficacy, and translational data for GLPG5101 and GLPG5201, evaluating seven-day vein-to-vein, fresh CD1
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancerUza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform Initial in vitro testing of uza-cel produced on Galapagos' decentralized manufacturing platform has shown encouraging data that support further clinical development Adaptimmune to receive initial payments of $100 million, comprising $70 million upfro
Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunologyExecuted agreements with BridGene Biosciences and Thermo Fisher Scientific, and investment in Frontier MedicinesTransferred Jyseleca® business to Alfasigma S.p.A., freeing up resources to invest in growth areasGroup net revenues in the first quarter of €100 millionCash and current financial investments of €3.6 billion on 31 March 2024Reconfirmed 2024 cash burni guidance of €280 million to €320 million, not including potential business development opportunities Webcast presentation with management on 3 May 2024, at 1
Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023Operational cash burni of €414.8 million, within guidance 2023 and year-to-date key updates: Transferred Jyseleca® business, including approximately 400 positions, to Alfasigma S.p.A.Achieved encouraging data from ongoing Phase 1/2 studies with CD19 CAR-T product candidates, GLPG5101 in rrNHL and GLPG5201, in rrCLL, with or without RTExpanded CAR-T pipeline with start of Phase 1/2 study with BCMA CAR-T product candidate GLPG5301 in rrMMEnrolled first patients in Phase 2 study with TYK2 inhibitor, G
First nine months 2023 key financials: Group revenues of €448.9 million Jyseleca® net sales of €82.1 million Cash and current financial investments of €3.8 billion at 30 September 2023Full year 2023 net Jyseleca® sales guidance of €100-€120 million and cash burn guidance of €380-€420 million reiterated Jyseleca® strategic evaluation completed: signed Letter of Intent to transfer the Jyseleca® (filgotinib) business to Alfasigma, including the European and UK Marketing Authorizations and development activities, and approximately 400 positions in 14 European countries Oncology pipeline: New encouraging data from ongoing CAR-T Phase 1/2 studies in relapsed/refractory chronic lymphocytic leuk
Half-year 2023 key financials Group revenues of €328.8 million Jyseleca® net sales of €54.3 million Cash and current financial investments of €3.9 billion on 30 June 2023 Full year 2023 net sales guidance for Jyseleca® lowered to €100-€120 million – 2023 cash burn guidance of €380-€420 million reiteratedOncology pipeline update – continued progress with point-of-care manufactured CAR-T candidates in hemato-oncology, including approval of the clinical trial application in Europe for BCMA CAR-T candidate in multiple myeloma Immunology pipeline update – start of Phase 3 study with filgotinib in axial spondyloarthritis; start of Phase 2 study with GLPG3667 in dermatomyositis; clinical trial ap
6-K - GALAPAGOS NV (0001421876) (Filer)
6-K - GALAPAGOS NV (0001421876) (Filer)
6-K - GALAPAGOS NV (0001421876) (Filer)
6-K - GALAPAGOS NV (0001421876) (Filer)
6-K - GALAPAGOS NV (0001421876) (Filer)
6-K - GALAPAGOS NV (0001421876) (Filer)
6-K - GALAPAGOS NV (0001421876) (Filer)
6-K - GALAPAGOS NV (0001421876) (Filer)
20-F - GALAPAGOS NV (0001421876) (Filer)
6-K - GALAPAGOS NV (0001421876) (Filer)
SC 13G/A - GALAPAGOS NV (0001421876) (Subject)
SC 13D/A - GALAPAGOS NV (0001421876) (Subject)
SC 13D - GALAPAGOS NV (0001421876) (Subject)
SC 13D/A - GALAPAGOS NV (0001421876) (Subject)
SC 13G/A - GALAPAGOS NV (0001421876) (Subject)
SC 13G/A - GALAPAGOS NV (0001421876) (Subject)
SC 13G - GALAPAGOS NV (0001421876) (Subject)
SC 13G/A - GALAPAGOS NV (0001421876) (Subject)
SC 13G - GALAPAGOS NV (0001421876) (Subject)
SC 13D - GALAPAGOS NV (0001421876) (Subject)